June 2026

Oral GLP-1 therapy is bringing obesity treatment to millions of patients who had never used weight-loss medicines before

The obesity treatment landscape is changing at remarkable speed, and Novo Nordisk has just added another milestone to the story.

The Danish pharmaceutical giant announced that Wegovy® (semaglutide) tablets 25 mg have surpassed 3 million prescriptions in the United States within just over five months of launch, making it one of the strongest pharmaceutical product launches by prescription volume in recent U.S. history.

In a groundbreaking advancement for precision medicine, doctors in Israel have successfully administered the world's first gene replacement therapy directly into the brain of an infant suffering from a rare and devastating genetic epilepsy disorder. The experimental treatment aims to restore the function of the defective WWOX gene, offering new hope to children affected by this life-threatening condition.

Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.